254 related articles for article (PubMed ID: 26379028)
41. Bone morphogenetic protein 2 and decorin expression in old fracture fragments and surrounding tissues.
Han XG; Wang DK; Gao F; Liu RH; Bi ZG
Genet Mol Res; 2015 Sep; 14(3):11063-72. PubMed ID: 26400336
[TBL] [Abstract][Full Text] [Related]
42. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.
Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849
[TBL] [Abstract][Full Text] [Related]
43. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
44. Cathepsin-S degraded decorin are elevated in fibrotic lung disorders - development and biological validation of a new serum biomarker.
Kehlet SN; Bager CL; Willumsen N; Dasgupta B; Brodmerkel C; Curran M; Brix S; Leeming DJ; Karsdal MA
BMC Pulm Med; 2017 Aug; 17(1):110. PubMed ID: 28793886
[TBL] [Abstract][Full Text] [Related]
45. Decorin: A Growth Factor Antagonist for Tumor Growth Inhibition.
Järvinen TA; Prince S
Biomed Res Int; 2015; 2015():654765. PubMed ID: 26697491
[TBL] [Abstract][Full Text] [Related]
46. [Prognostic significance of morphology in multiple myeloma].
Al-Sahmani M; Trnavská I; Antošová M; Antošová L; Kissová J; Kaisarová B; Adam Z; Buliková A; Penka M; Hájek R
Klin Onkol; 2012; 25(2):103-9. PubMed ID: 22533884
[TBL] [Abstract][Full Text] [Related]
47. Decreased plasma decorin levels following acute ischemic stroke: correlation with MMP-2 and differential expression in TOAST subtypes.
Xu YZ; Zhao KJ; Yang ZG; Zhang YH; Zhang YW; Hong B; Liu JM
Mol Med Rep; 2012 Dec; 6(6):1319-24. PubMed ID: 23026977
[TBL] [Abstract][Full Text] [Related]
48. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
49. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.
Mai EK; Hielscher T; Kloth JK; Merz M; Shah S; Raab MS; Hillengass M; Wagner B; Jauch A; Hose D; Weber MA; Delorme S; Goldschmidt H; Hillengass J
Haematologica; 2015 Jun; 100(6):818-25. PubMed ID: 25795721
[TBL] [Abstract][Full Text] [Related]
50. [Effects of overexpression of decorin on matrix metalloproteinases 2 and 9 in rat mesangial and tubular cells].
Dong FQ; Li H; Wu F; Yao HP
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3444-7. PubMed ID: 19159581
[TBL] [Abstract][Full Text] [Related]
51. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
52. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
53. Biology and treatment of multiple myeloma.
Tosi P; Gamberi B; Giuliani N
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):81-6. PubMed ID: 16399590
[TBL] [Abstract][Full Text] [Related]
54. Surface functionalization of electrospun scaffolds using recombinant human decorin attracts circulating endothelial progenitor cells.
Hinderer S; Sudrow K; Schneider M; Holeiter M; Layland SL; Seifert M; Schenke-Layland K
Sci Rep; 2018 Jan; 8(1):110. PubMed ID: 29311692
[TBL] [Abstract][Full Text] [Related]
55. Effect of complete response on outcome following autologous stem cell transplantation for myeloma.
Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Larson D; Therneau TM; Kyle RA; Litzow MR; Greipp PR; Gertz MA
Bone Marrow Transplant; 2000 Nov; 26(9):979-83. PubMed ID: 11100277
[TBL] [Abstract][Full Text] [Related]
56. [Dose-intensive immunochemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of 29 newly diagnosed young patients with medium/high risk diffuse large B-cell lymphoma].
Yi S; Liu W; Lyu R; Li Z; Xu Y; Sui W; Huang W; Wang T; Deng S; Liu H; Fu M; Zou D; Qiu L
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):546-50. PubMed ID: 24985182
[TBL] [Abstract][Full Text] [Related]
57. Bone marrow megakaryocytes, soluble P-selectin and thrombopoietic cytokines in multiple myeloma patients.
Lemancewicz D; Bolkun L; Mantur M; Semeniuk J; Kloczko J; Dzieciol J
Platelets; 2014; 25(3):181-7. PubMed ID: 23855381
[TBL] [Abstract][Full Text] [Related]
58. Characterisation of colorectal cancer by hierarchical clustering analyses for five stroma-related markers.
Ito S; Koshino A; Wang C; Otani T; Komura M; Ueki A; Kato S; Takahashi H; Ebi M; Ogasawara N; Tsuzuki T; Kasai K; Kasugai K; Takiguchi S; Takahashi S; Inaguma S
J Pathol Clin Res; 2024 Jul; 10(4):e12386. PubMed ID: 38890810
[TBL] [Abstract][Full Text] [Related]
59. Decorin-mediated inhibition of proliferation and migration of the human trophoblast via different tyrosine kinase receptors.
Iacob D; Cai J; Tsonis M; Babwah A; Chakraborty C; Bhattacharjee RN; Lala PK
Endocrinology; 2008 Dec; 149(12):6187-97. PubMed ID: 18703624
[TBL] [Abstract][Full Text] [Related]
60. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
